Who makes [14C]-linerixibat intravenous infusion?

[14C]-linerixibat intravenous infusion is developed by GlaxoSmithKline.

What development phase is [14C]-linerixibat intravenous infusion in?

[14C]-linerixibat intravenous infusion is in Phase 1.

What are the side effects of [14C]-linerixibat intravenous infusion?

Common side effects include Diarrhoea, Abdominal discomfort, Constipation, Back pain, Headache, Erythema.

Last reviewed 2026-05-14 · How we verify

[14C]-linerixibat intravenous infusion

GlaxoSmithKline · Phase 1 active Small molecule Quality 5/100

At a glance

Generic name	[14C]-linerixibat intravenous infusion
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Diarrhoea
Abdominal discomfort
Constipation
Back pain
Headache
Erythema

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-linerixibat intravenous infusion CI brief — competitive landscape report
[14C]-linerixibat intravenous infusion updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI